ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1617

Burden of Adverse Childhood Experiences in Pediatric Chronic Pain and Rheumatic Disease
Abstract Number: 1618

Disease Flares in CANDLE/PRAAS with Dose Reductions of Baricitinib
Abstract Number: 1619

Where Do Multisystem Inflammatory Syndrome in Children (MIS-C) and Pediatric COVID-19 Fit Under the Cytokine Storm Syndrome Umbrella?
Abstract Number: 1620

Pediatric Onset (< 16 Years) Non-infectious Uveitis: Results from Spanish National Registry
Abstract Number: 1621

Self-reported Transition Readiness of Adolescent Patients with Rheumatologic Disease: Do the Parents Agree?
Abstract Number: 1622

Mind the Gap: The Experience of Adolescents in a Rheumatology Transition Clinic
Abstract Number: 1623

Impact of the COVID-19 Pandemic on Presentation of JIA to Pediatric Rheumatology Care in Canada
Abstract Number: 1624

Patient-Reported Care Utilization, Socioeconomic Status, and Health Status Among Young Adults with JIA
Abstract Number: 1625

Clinical Characteristics of Multisystem Inflammatory Syndrome in Children: A Provincial Cohort
Abstract Number: 1626

Use of Total Hip Arthroplasty in Patients Under 21 Years Old: A U.S. Population Analysis
Abstract Number: 1627

Long Term Follow-Up of Patients with Childhood-Onset Lupus Nephritis After Transition to Adult Care
Abstract Number: 1628

Reproductive Health Knowledge Gaps, Needs, and Barriers Identified by Pediatric Rheumatology Providers
Abstract Number: 1629

Effect of Drug Withdrawal on Interleukin-1 or Interleukin-6 Inhibitor Associated Diffuse Lung Disease
Abstract Number: 1630

Multisystem Inflammatory Syndrome in Children: Clinical Characteristics and Predictors for Length of Hospitalization
Abstract Number: 1631

Predictive Factors for Lack of Response to Treatment in a Long-term Cohort of Patients with Juvenile Idiopathic Arthritis-associated Uveitis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].